DNLIHealthcare · BiotechnologyThe 20 Wall Street analysts covering Denali Therapeutics, Inc. hold a median 12-month price target of $35 — +51.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 1 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Denali Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (77): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (43): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Size (28): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Denali Therapeutics, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on DNLI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +51.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 July 2026 | Morgan Stanley | Maintains | Overweight | $35 → $36 |
| 16 July 2026 | Deutsche Bank | Maintains | Buy | $31 → $35 |
| 13 July 2026 | JP Morgan | Reinstates | Overweight | $29 |
| 26 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 14 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 11 May 2026 | BTIG | Reiterates | Buy | — |
| 8 May 2026 | Wedbush | Maintains | Outperform | — |
| 22 Apr 2026 | Leerink Partners | Maintains | Outperform | — |
| 7 Apr 2026 | Baird | Maintains | Outperform | — |
| 26 Mar 2026 | Baird | Maintains | Outperform | — |
| 26 Mar 2026 | Goldman Sachs | Maintains | Buy | — |
| 26 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Mar 2026 | Morgan Stanley | Maintains | Overweight | — |
| 26 Mar 2026 | Stifel | Maintains | Buy | — |
| 25 Mar 2026 | BTIG | Maintains | Buy | — |
| 2 Mar 2026 | BTIG | Maintains | Buy | — |
| 24 Feb 2026 | Wolfe Research | Initiates | Peer Perform | — |
| 6 Feb 2026 | BTIG | Reiterates | Buy | — |
| 7 Jan 2026 | UBS | Assumes | Buy | $25 |
| 11 Dec 2025 | Wedbush | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 26% of US stocks
Cheaper than 79% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
Higher than 21% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DNLI appears on the weeks it earns a place.
Denali Therapeutics announced it will report its second quarter 2026 financial results and business highlights on August 6, 2026.
Why it matters — This scheduled earnings announcement provides a regular update on the company's financial performance and business progress for the quarter.
The 20 Wall Street analysts covering Denali Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $25 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 20 analysts covering Denali Therapeutics, Inc., 19 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Denali Therapeutics, Inc. 57 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Denali Therapeutics, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (77 of 100).
No one can know that. What the data says: the median 12-month target from 20 analysts implies +51.2% from the last close, and Ticker Nerd's factor model ranks Denali Therapeutics, Inc. 57 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Denali Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DNLI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $42 over the next 12 months.
Denali Therapeutics, Inc. returned +72.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutics to address neurodegenerative and lysosomal storage diseases.
The most recent item we track (GlobeNewsWire, 27 July 2026): "Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026". Denali Therapeutics announced it will report its second quarter 2026 financial results and business highlights on August 6, 2026.
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutics to address neurodegenerative and lysosomal storage diseases. The company engineers product candidates using proprietary technologies such as Antibody Transport Vehicle (ATV) and Enzyme Transport Vehicle (ETV) to enable effective delivery across the blood-brain barrier, targeting challenging central nervous system disorders. Its pipeline includes programs like DNL310 (Tividenofusp alfa) for Hunter syndrome (MPS II), DNL126 for MPS IIIA (Sanfilippo Syndrome A), DNL343 (eIF2B activator) for amyotrophic lateral sclerosis, BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson's disease, Eclitasertib (DNL758, RIPK1 inhibitor) for peripheral inflammatory diseases, and others such as TAK-594/DNL593 for frontotemporal dementia-granulin and initiatives targeting TREM2 and Tau. Denali Therapeutics Inc. advances these candidates through clinical development, emphasizing innovative solutions for unmet needs in neurology and rare genetic disorders. Founded in 2013 and headquartered in South San Francisco, California, it plays a key role in the biotechnology sector dedicated to neurodegeneration.
CEO Dr. Ryan J. Watts Ph.D. · 507 employees · United States · https://www.denalitherapeutics.com